Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
My American Story
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
My American Story
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
61.15
-1.10 (-1.77%)
Official Closing Price
Updated: 4:10 PM EDT, Sep 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
93
94
Next >
Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder
↗
September 20, 2026
The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.
Via
The Motley Fool
Topics
Intellectual Property
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
↗
September 18, 2026
AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.
Via
The Motley Fool
Topics
Intellectual Property
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
September 18, 2026
From
Bristol Myers Squibb
Via
Business Wire
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
September 17, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Supernus Pharmaceuticals (NAS...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Bristol-Myers Squibb (NYSE:BMY) Passes the Dividend Screen, but Payout Sustainability Is the Key Question
↗
September 10, 2026
Via
Chartmill
Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup
↗
September 05, 2026
Via
Chartmill
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
September 17, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend
September 16, 2026
From
Bristol Myers Squibb
Via
Business Wire
3 Healthcare Stocks That Fall Short
September 14, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
Via
StockStory
Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone?
↗
September 13, 2026
As management tackles key issues head-on, Bristol Myers Squibb stock offers a steady 4% yield, with further upside potential.
Via
The Motley Fool
Topics
Intellectual Property
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
September 10, 2026
Via
Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
September 10, 2026
Via
Investor Brand Network
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
September 08, 2026
From
Bristol Myers Squibb
Via
Business Wire
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026
From
BioMedWire
Via
GlobeNewswire
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
↗
September 03, 2026
Both have attracted considerable attention from Wall Street recently.
Via
The Motley Fool
Is BioNTech Stock a No-Brainer Buy on the Dip?
↗
September 02, 2026
The company is coming back into the spotlight thanks to recent developments.
Via
The Motley Fool
2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now
↗
September 02, 2026
If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector.
Via
The Motley Fool
Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest
August 31, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
3 Reasons to Sell BMY and 1 Stock to Buy Instead
August 31, 2026
Even though Bristol-Myers Squibb (currently trading at $66.44 per share) has gained 6.6% over the last six months, it has lagged the S&P 500’s 12.3% return d...
Via
StockStory
Topics
Stocks
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
August 29, 2026
From
Bristol Myers Squibb
Via
Business Wire
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
↗
August 29, 2026
Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.
Via
The Motley Fool
Topics
Intellectual Property
1 S&P 500 Stock with Promising Prospects and 2 Facing Challenges
August 28, 2026
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Via
StockStory
Topics
Stocks
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology
From
MarketNewsUpdates.com
Via
GlobeNewswire
3 Dividend Stocks to Hold for the Next 10 Years
↗
August 25, 2026
These healthcare leaders are unlikely to suspend their dividend programs.
Via
The Motley Fool
Topics
Artificial Intelligence
Intellectual Property
Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset?
↗
August 21, 2026
IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.
Via
The Motley Fool
Topics
ETFs
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
August 20, 2026
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Oc...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)
August 19, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now
↗
August 18, 2026
Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
93
94
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today